A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs
By Y. Gordon, E. Romanowski, A. McDermott. Current Eye Research, 2005
702 citations recorded by the source corpus.
Subfields: Dermatology, Microbiology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/3eac1d09639e707e88c53f7ab6bb3dcad9176929
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Microbiology
- M. Malmsten
- A. Schmidtchen
- Mukesh Pasupuleti
- Christopher D. Fjell
- A. Giuliani
- G. Pirri
- S. F. Nicoletto
- Robert E. W. Hancock
In Organic Chemistry
Citations in the corpus
- Designing antimicrobial peptides: form follows function (2011, background): “There are clear precedents for cationic peptides having clinical efficacy 183 ; the cationic lipopeptide polymyxin is the lastresort drug for treat ing multiresistant Pseudomonas spp. and Acinetobacter spp. infections, the cyclic cationic peptide gramicidin S is highly used in topical ointments…”
- Antimicrobial peptides: an overview of a promising class of therapeutics (2007, background): “P113 (developed by Periodontix, USA, then acquired by Demegen, USA) is a 12-amino-acid cationic peptide based on histatins, naturally occurring AMPs in the saliva [86] that demonstrated excellent in vitro activity against Candida albicans and common Gram-positive and Gram-negative pathogens.”
- Application of antimicrobial peptides in agriculture and food industry (2009, background): “Though not yet released as drugs, many AMPs have been assessed as potential therapeutics which could replace the abolished antibiotics ( Gordon et al. 2005; Schro ¨der and Harder 2006).”
- Antimicrobial peptides: key components of the innate immune system (2012, background): “Without doubt, antibiotics are the most successful antiinfective agents used to control infectious diseases and until the last decade or so, the pharmaceutical industry has continuously upgraded/modified existing antibiotics and developed newer ones (Gordon et al., 2005; Hancock, 2007).”
- TFOS DEWS II pathophysiology report. (2017, unknown): “several antimicrobial proteins and peptides [103].”